Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List

A board-certified RN and Family Nurse Practitioner argues that the FDA should preserve access to compounded peptide therapies for individualized patient care. The commenter emphasizes that compounding is essential for patients who do not respond well to conventional medications and highlights their own successful clinical and personal experience with these treatments.

A registered nurse and patient supports preserving access to compounded peptide therapies, arguing that they provide essential, individualized treatment options for proactive healthcare. The commenter warns that restricting access will drive patients toward unregulated, unsafe gray-market products.

The commenter, a Registered Dietitian Nutritionist, supports the FDA's consideration of policies that preserve access to individualized compounded medications. They argue that personalized treatments are important for patients whose needs are not met by commercially available options.

The commenter, a patient who has successfully used physician-supervised compounded peptide therapy to manage metabolic health and perimenopause, supports the action of preserving patient access to these therapies. She emphasizes the importance of personalized medicine and requests that the FDA maintain options for appropriately prescribed compounded treatments.

A patient who has successfully used compounded peptide therapy for weight loss advocates for the preservation of access to compounded medications. They argue that personalized treatment plans are essential for patient well-being and that limiting access could drive patients toward unregulated, unsafe alternatives.

An individual expresses support for the action by arguing that it preserves patient choice and access to individualized care, specifically regarding pharmaceutical-grade peptides. The commenter emphasizes the importance of maintaining access to these substances for personal health goals.

Kathy Wieliczko, a nurse practitioner, supports the preservation of access to individualized compounded peptide therapies. She argues that restricting these therapies under clinical oversight would not improve safety but would instead push patients toward unregulated sources.

The commenter, an occupational therapist and health coach, opposes the proposed restrictions on bulk drug substances. They argue that restricting access to peptides will drive patients toward unlicensed providers and advocate for the ability of patients and providers to make individualized treatment decisions.

The commenter, an emergency room nurse and patient, supports maintaining access to regulated compounding of peptide medications. They argue that providing these medications through legitimate compounding pharmacies ensures patient safety and prevents individuals from seeking unregulated, potentially dangerous alternatives.